People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

As part of the move, Caremark will also drop Eli Lilly's weight loss drug Zepbound from ... "In our view, the Novo/CVS deal does not represent the beginning of an obesity pricing war between ...

INDIANAPOLIS — Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health ... part of a wave of obesity medications ...

Investing.com -- CVS Caremark announced a partnership with Novo Nordisk (NYSE:NVO) to expand access to Wegovy, a GLP-1 drug for obesity, at a more affordable price. Starting July 1, 2025, Wegovy will ...

INDIANAPOLIS — Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs ... Wegovy and Zepbound are part of ...